Amersham Biosciences has extended its CodeLink microarray range with the launch of its Human P450 SNP Bioarray. The product genotypes 110 single nucleotide polymorphisms (SNPs) within nine P450 genes for genotyping and pharmacogenomic profiling.
The product covers the CYP1A1, 1A2, 1B1, 2C9, 2C19, 2D6, 2E, 3A4, and 3A5 P450 genes and is designed for screening clinical trial populations to determine their toxicogenetic profiles and for the discovery of novel associations between P450 genotypes and phenotypes.
Amersham notes that the bioarray contains a set of four identical arrays of 110 SNPs to enable the testing of four individual samples simultaneously. Customers benefit from the speed and flexibility of the system and the ability to individually score each sample with high accuracy.
"The new CodeLink Human P450 SNP Bioarray will aid the discovery of clinically significant genetic markers in populations studies for researchers involved in high throughput toxicogenomic screening," said Sam Raha, vice president of CodeLink at Amersham.
Earlier this month, Amersham launched a CodeLink bioarray covering the mouse genome to aid in drug target identification, pathway characterisation and drug effect predictions.